Thrive Capital Management (Pennsylvania) Portfolio holdings
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR Portfolio S&P 500 Growth ETF
SPYG
|
+$1.87M |
| 2 |
iShares US Treasury Bond ETF
GOVT
|
+$1.5M |
| 3 |
iShares Core Moderate Allocation ETF
AOM
|
+$1.43M |
| 4 |
iShares Core Dividend Growth ETF
DGRO
|
+$1.34M |
| 5 |
Chevron
CVX
|
+$1.09M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares Short Maturity Bond ETF
NEAR
|
+$1.59M |
| 2 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$1.16M |
| 3 |
iShares Ultra Short Duration Bond Active ETF
ICSH
|
+$1.01M |
| 4 |
iShares Floating Rate Bond ETF
FLOT
|
+$946K |
| 5 |
GSK
GSK
|
+$920K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 8.7% |
| 2 | Healthcare | 7.05% |
| 3 | Consumer Staples | 3.65% |
| 4 | Consumer Discretionary | 2.99% |
| 5 | Communication Services | 2.91% |
Similar funds
Thrive Capital Management (Pennsylvania)'s Q2 2021 Portfolio in Review
As of Q2 2021, Thrive Capital Management (Pennsylvania) held 115 positions worth $129M, up 20% from $107M the previous quarter. Its ten largest holdings account for 37% of the portfolio.
Thrive Capital Management (Pennsylvania) deployed $17.1M of net new capital in Q2 2021, opening 9 new positions and adding to 66 existing holdings. Its largest new stake was Chevron: 10,341 shares worth $1.08M.
By sector, the portfolio is most concentrated in Technology at 8.7% of assets, up from 7.5% a quarter earlier, followed by Healthcare and Consumer Staples.
On the sell side, the largest reduction was iShares Short Maturity Bond ETF, an estimated $1.59M trimmed.
- Thrive Capital Management (Pennsylvania)'s largest Q2 2021 buy was Chevron: 10,341 shares worth $1.08M.
- Thrive Capital Management (Pennsylvania) added most to State Street SPDR Portfolio S&P 500 Growth ETF in Q2 2021, an estimated $1.87M increase.
- Thrive Capital Management (Pennsylvania)'s biggest Q2 2021 reduction was iShares Short Maturity Bond ETF, cutting an estimated $1.59M.
- Thrive Capital Management (Pennsylvania) fully exited GSK in Q2 2021, selling an estimated $920K.
- Thrive Capital Management (Pennsylvania)'s ten largest holdings make up 37% of its $129M portfolio in Q2 2021.
- Thrive Capital Management (Pennsylvania) opened 9 new positions and closed 6 in Q2 2021.
- Thrive Capital Management (Pennsylvania)'s portfolio value rose 20% quarter-over-quarter to $129M.
Based on Thrive Capital Management (Pennsylvania)'s 13F filing for Q2 2021, filed 6 Aug 2021.